{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-038800","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2023-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.137133+00:00","generated_at":"2026-06-09T04:58:54.682239+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Indaptus reports Phase 1 interim data for Decoy20: biomarker activation & transient AEs in first cohort","bullets":["Interim data from first cohort (n=4) of Phase 1 INDP-D101 trial for Decoy20, dosed at 7x10^7 killed bacteria via 1-hour IV infusion.","Treatment-related AEs included changes in hemodynamic parameters, transaminase elevations, lymphopenia; all resolved within 30 min to 3 days.","Transient activation of innate and/or adaptive immune biomarkers observed in all patients as of Aug 31, 2023.","Company to present full interim data at SITC 38th Annual Meeting on November 4, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-038800","json":"https://secwatch.observer/filing/0001493152-23-038800.json","markdown":"https://secwatch.observer/filing/0001493152-23-038800.md","text":"https://secwatch.observer/filing/0001493152-23-038800.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223038800/0001493152-23-038800-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223038800/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T04:58:54.682239+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}